I'll research CRL (Charles River Laboratories) before writing the preview. Let me gather recent filings, earnings history, and news.Let me pull the recent earnings materials and price history.Let me get the Q1 2026 earnings release details, recent stock price action, and any recent news.Let me get the year-ago Q2 2025 numbers for comparison and recent news/analyst actions.Let me pull the Q4 2025 release for full-year 2025 actuals and the setup of 2026 guidance.# Charles River Laboratories (CRL) — Q2 2026 Earnings Preview
This is the quarter the bull case has to start proving itself. After a deliberately weak Q1 2026 (organic revenue ‑1.5%, non-GAAP EPS down 12% to $2.06, margins compressed by discrete headwinds), management told investors Q2 would be the inflection point on profitability, ahead of a promised return to organic growth in the second half. The print lands with the stock near 52-week highs and up ~29% since the Q1 report, so the bar has risen materially even though the reported P&L will look ugly year-over-year.
1. The Q2 margin/EPS inflection — did they deliver? On the Q1 call, CFO Glenn Coleman explicitly guided Q2 non-GAAP EPS to increase at least 30% sequentially from $2.06 — i.e., roughly $2.68+ — driven by the abatement of Q1's discrete headwinds (CEO-transition stock comp, NHP sourcing costs/study starts in DSA, and NHP shipment timing in RMS) plus the first margin benefit from divestitures. Management said all three segments should show sequential operating margin improvement. This is the single most important checkpoint: Q1 was framed as "trust us, the back half gets much better," and Q2 is the first evidence.
2. A messy year-over-year optics problem — set expectations correctly. The year-ago Q2 2025 was a genuinely strong quarter: revenue of $1.03 billion and non-GAAP EPS of $3.12 (+11% YoY, with DSA non-GAAP margin of 27.4%). Against that comp, Q2 2026 will look like a decline on the headline: - Reported revenue was guided to fall at a mid- to high-single-digit rate YoY, mostly from divestitures (CDMO/Cell Solutions closed May 6; certain European Discovery sites closed in May — together ~5% of revenue) plus a now-less-favorable FX. - Organic revenue was guided to a low-single-digit decline, similar to Q1. - So EPS down YoY (~$2.68 vs. $3.12) is expected and not the story; the sequential ramp and the forward trajectory are.
3. DSA bookings and book-to-bill — the real leading indicator. DSA is the core (roughly 60% of revenue). The entire second-half-recovery thesis rests on bookings converting to revenue. Track: - Net book-to-bill (Q1 was 1.04x; management expects the full-year average above 1.0x but warned it won't be above 1.0x every quarter). - Net bookings (Q1 was $622M, above the $600M threshold) and backlog ($1.92B at end of Q1). - Proposal volume, which management flagged as up high-single-digits YoY and rising sequentially three quarters in a row — the tell for whether bookings momentum continues. A book-to-bill dip below 1.0x or softening proposals would undercut the 2H growth call.
4. Full-year guidance — reaffirm, raise, or trim? Current 2026 framework: - Organic revenue ‑1.5% to ‑0.5%; reported ‑5.5% to ‑4.0% (after the FX cut in Q1). - Non-GAAP EPS $10.80–$11.30 (5–10% growth over 2025's $10.28), including ~$0.10 of divestiture accretion. - ~120–150 bps of operating margin expansion, with 2H operating margin >500 bps above 1H (over half of that from completed M&A/divestitures).
Given the improving biotech funding backdrop and the stock's run, the debate is whether management nudges the range up or at least raises the low end. A simple reaffirmation may disappoint a stock that has priced in acceleration.
| Segment | Q1'26 organic | Key Q2 watch items |
|---|---|---|
| DSA (~60%) | ‑1.4% | Path back toward organic growth; NHP sourcing cost roll-off; Safety Assessment volumes; margin recovery off Q1's 21.0% |
| RMS (~21%) | ‑5.5% | Q1 was the "lowest point for the year" on NHP shipment timing — expect sequential rebound; continued China small-model strength vs. soft North America |
| Manufacturing (~19%) | +2.9% | Microbial Solutions (Endosafe/Celsis) momentum; Biologics Testing rebound as it anniversaries a client-specific headwind; margin lift now that dilutive CDMO is divested |
Manufacturing is the cleaner growth story and its margin should structurally step up post-CDMO exit (segment non-GAAP margin was already 25.9% in Q1). RMS bouncing off a Q1 trough and DSA inflecting are the swing factors.
CRL has been one of the sharper recoveries in tools/CRO: shares are up roughly 55% from the mid-May 2026 low (~$151), ~29% since the Q1 report, and ~40% over the past year, closing around $234 on Aug 4 — near the late-July high of ~$240. That momentum reflects optimism on the biotech funding recovery, the margin inflection, and portfolio simplification. The risk: a lot of good news is now in the price. Even an in-line quarter with a reaffirmed guide could see profit-taking, while the reward case likely requires (a) a clean beat on the Q2 sequential EPS ramp, (b) a book-to-bill holding ≥1.0x with strong proposals, and (c) a guidance raise or confident 2H growth commentary.
The market is treating this as the quarter where "second-half recovery" stops being a promise and starts becoming a trend. Delivery on the sequential margin ramp plus a healthy bookings signal is what justifies the run into the print; anything softer risks a pullback given elevated expectations.
Note: All figures above are non-GAAP unless stated; GAAP results carry large divestiture-related and amortization items (Q1 2026 GAAP was a $(0.30) loss due to a $118M loss on assets held for sale). Focus on organic revenue, bookings, and non-GAAP margin/EPS for the underlying trend.